Introduction
============

Epstein-Barr virus (EBV) is a human gamma-1 herpes virus which infects more than 95% of the population ([@B50]). This virus is strongly associated with a range of lymphoid and epithelial malignancies and autoimmune diseases ([@B26]; [@B33]; [@B38]). EBV preferentially infects naïve B cells at oropharyngeal lymphoid tissues and subsequently establishes a persistent infection in the circulating memory B cells ([@B2]; [@B37]). Once EBV establishes a latent infection, it downregulates the expression of most of the viral genes thereby evading the host immune responses ([@B22]). Primary EBV infection typically occurs during childhood without apparent clinical symptoms and evolves into a non-symptomatic persistent virus carrier state ([@B17]). Delayed primary infection in some individuals leads to the development of a self-limiting disease called infectious mononucleosis (IM) ([@B21]; [@B46]; [@B30]; [@B37]). EBV has transforming capability as manifested by the occurrence of uncontrolled malignant B cell proliferation in immunosuppressed individuals such as solid organ or stem cell transplantation recipients ([@B29]).

The understanding of the mechanisms by which the human immune system controls EBV infection is incomplete due to the difficulties in identifying specific EBV peptides across a wide range of HLA alleles and the fact that EBV can express a large number of lytic and latent proteins displaying hierarchy of immunodominance in its life cycle ([@B35]). IM, which is characterized by large expansions of CD8+ T cells and NK cells, provides an excellent model for the study of immune responses against EBV ([@B6]; [@B37]). The current knowledge on EBV-specific T-cell immunity is mostly derived from studies of IM peripheral blood mononuclear cell (PBMC) samples using either MHC-specific tetramers to determine the percentages of EBV-specific T cells or Enzyme-linked immunosorbent spot (ELISPOT) assay to detect the production of interferon-gamma (IFN-γ) by EBV-specific CD8+ T cells ([@B28]; [@B40]; [@B16]; [@B18]). However, the functional roles of CD4+ and CD8+ T cells in the control of EBV infection are not completely understood.

Polyfunctional T cells (PFC) are T cells which have multiple functions, such as degranulation of cytotoxic proteins and production of multiple cytokines such as IFN-γ, tumor necrosis factor-alpha (TNF-α), interleukin-2 (IL-2) simultaneously. Accumulating evidence suggests that PFC are associated with more effective control of chronic microbial infections including human immunodeficiency virus (HIV), hepatitis C virus (HCV), and cytomegalovirus (CMV) ([@B15]; [@B7]; [@B10]; [@B11]; [@B36]). We and other groups have studied EBV-specific PFC in long term carriers and found that they produced more cytokines per cell than the single functional T cells and may be functionally superior ([@B45]; [@B31]). Another study found that frequencies of PFC were higher in HIV non-progressors than in progressors ([@B4]). Interestingly, a recent study demonstrated that polyfunctional and IFN-γ mono-functional CD4+ T cells are molecularly distinct and the polyfunctional gene signatures in response to *Plasmodium falciparum* infection and influenza infection were highly conserved ([@B5]). These findings support the notion that PFC contribute to more robust T-cell immunity in the control of virus infections. However, how PFC arise during primary EBV infection and evolve over time as well as their role in the long term control of EBV from primary infection stage to long term persistence remain unclear.

Here, we conducted a longitudinal study to assess the development and maturation of T cell responses to EBV from acute infection stage to long term persistence in two primary infection cohorts in children, those presenting as IM and those as asymptomatic primary infection (AS). ELISPOT assay was first performed to detect the IFN-γ secreting CD8+ T cell responses upon stimulation by HLA class I-specific peptides of EBV lytic and latent proteins in 18 longitudinally followed IM cases and 12 AS cases. A 9-color flow cytometric assay which simultaneously delineates five parameters: production of IFN-γ, perforin, TNF-α and IL-2, and surface mobilization of CD107a (degranulation marker), upon stimulation by overlapping peptide pools of 4 EBV lytic and 5 latent cycle proteins was then performed to further evaluate the EBV-specific CD4+ and CD8+ PFC responses in another 11 IM cases. Corresponding PBMC and plasma viral loads were determined as measurement of viral control. T cell lysis against autologous lymphoblastoid cell line (LCL) in three IM patients was measured to assess the cytotoxic function of the EBV-specific T cells.

Materials and Methods {#s1}
=====================

Subject Recruitment
-------------------

Two cohorts of study subjects consisting of 29 children with infectious mononucleosis (IM) and 12 with asymptomatic primary infection (AS) were recruited. Serological screening for EBV was performed to confirm their primary infection state of EBV (Supplementary Table [1](#SM1){ref-type="supplementary-material"}). Children with positive viral capsid antigen (VCA)-IgM, VCA-IgG, negative EBNA1 IgG and showed clinical symptoms were identified as IM subjects. For those who showed a serological profile of primary EBV infection with positive or negative VCA-IgM, positive VCA-IgG, negative EBNA1 and low VCA-IgG avidity without symptoms were recruited as AS subjects. As the maturation of VCA-IgG antibody from low to high avidity takes up to 6 months, AS patients were estimated to have been infected by EBV within a period of 6 months. Heparinized peripheral blood samples were collected at the time of first examination and subsequently, at 1, 2--5, and 6--12 months after diagnosis for the longitudinal study. Plasma was isolated and stored in -80°C until use. Peripheral blood mononuclear cells (PBMC) were isolated by standard Ficoll-Hypaque density gradient method. Collected PBMC were cryopreserved in fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, United States) with 10% DMSO under liquid nitrogen until use. All patient samples were handled as potential biohazardous material following the institutional safety procedures. The study protocol was approved by the Institutional Review Board of the University of Hong Kong. Informed written consent was obtained from each participant prior to the study.

### DNA Extraction, HLA Typing and Quantitative PCR (qPCR)

Qiagen DNeasy blood mini kit (Qiagen) and NucliSENS easyMag instrument (BioMerieux) were used to extract DNA from PBMC and plasma, respectively, in accordance to the manufacturer's instruction. Part of the DNA samples were transferred to The University of Birmingham and the HLA laboratory in Queen Mary Hospital, The University of Hong Kong for HLA typing. The HLA types of all subjects recruited in ELISPOT assay were documented (Supplementary Table [3](#SM3){ref-type="supplementary-material"}). The rest of the DNA was used to measure the EBV loads by qPCR with ABI PRISM 7900 sequence detector (Applied Biosystems, United States). EBV loads in PBMC were determined by the amplification of viral DNA polymerase (Pol, BALF5) sequence. Human β2 microglobulin sequence was detected as an internal control. Plasma EBV loads were quantified by expression of the BamH1W repeats in the EBV genome.

Synthetic EBV Peptides
----------------------

Two types of synthetic peptides consisting of 24 HLA class I-restricted peptides and 9 overlapping peptide pools were utilized. All HLA class I-restricted peptides were kindly provided by Professor Alan B. Rickinson (The University of Birmingham, Birmingham, United Kingdom) and their sequences and identities are listed in Supplementary Table [2](#SM2){ref-type="supplementary-material"}. The HLA class-I restricted peptides were diluted into 2 μg/mL in CTL-Test Medium (Cellular Technology Limited, United States) and 100 μl was added to each well in 96-well plate. Fifteen-mer peptides overlapped by 11 amino acids spanning each of the EBV latent proteins, EBNA1, EBNA3A, EBNA3B, EBNA3C and LMP2 and the lytic proteins, BZLF1, BRLF1, BMLF1 and GP350 were purchased from JPT Peptide Technologies, Berlin, Germany. The lyophilized peptide pools of each EBV protein were reconstituted according to manufacturer's instruction. Final concentration of overlapping peptides was 10 μg/ml per million cells. The HLA class-I restricted peptides were used in the ELISPOT assay and overlapping peptides were used in the flow cytometric analysis.

ELISPOT Assay
-------------

Interferon-gamma (IFN-γ) producing EBV-specific CD8+ T cell responses were quantified in duplicate by ELISPOT assay. Cryopreserved PBMC and HLA class-I restricted peptides were used. The peptide epitopes tested for each individual were listed in Supplementary Table [3](#SM3){ref-type="supplementary-material"}. Wells containing phytohemagglutinin (PHA) (1 mg/ml) were used as positive control and wells with only cells were used as a negative control. IFN-γ producing cells were counted by immunospot plate reader (Cellular Technology Limited-ImmunoSpot S5 Macro Analyzer) and expressed in spot-forming cells (SFC)/10^6^ PBMC. Spots were defined as positive when the SFC/10^6^ PBMC was higher than 20. Only positive results were reported in the present study.

Expansion of T Cells
--------------------

For better sensitivity of the flow cytometric analysis, the EBV lytic and latent protein-specific T cells were expanded by adding recombinant IL-4 and IL-7 according to a protocol provided by Professor Cliona M Rooney, Baylor College of Medicine, United States ([@B19]; [@B12]). In brief, cryopreserved PBMC were thawed and washed with 10% FBS in RPMI 1640. Cells were seeded and incubated with relevant peptide pools, IL-4 and IL-7 at 2 μg/ml, 1000 U/ml and 10 ng/ml (PreproTech) respectively for 5 days at 37°C, 5% CO~2~ in 24-well plate (1 × 10^6^ PBMC/ml). PBMC cultured with IL-4 and IL-7 for 5 days were used as negative control.

Re-stimulation of T Cells
-------------------------

After expansion of T cells for 5 days, PBMC were rested overnight at 37°C, 5% CO~2~ prior to peptide re-stimulation. PBMC were then re-stimulated with corresponding overlapping peptide pools at 2 μg/ml, together with PE-Cy5-conjugated anti-CD107a monoclonal antibody (BD Biosciences Pharmingen, United States), co-stimulatory reagents containing anti-CD28 monoclonal antibody at 1 μg/ml (BD Pharmingen, United States), anti-CD49d monoclonal antibody at 1 μg/ml (BD Pharmingen, United States) and brefeldin A at 10 μg/ml (BD Biosciences Pharmingen, United States) for 6 h at 37°C, 5% CO~2~. Cells stimulated with 1 μg/ml staphylococcal enterotoxin B (SEB) were used as a positive control whereas unstimulated PBMC were used as negative control. Both positive and a negative controls were treated with the same costimulatory reagents.

Flow Cytometric Analysis
------------------------

After incubation for 6 h, the treated cells were washed in PBS and stained with Aqua Blue Dye (Invitrogen, United States) for 20 min for dead cell exclusion. APC-Cy7-conjugated anti-CD3 (BD Pharmingen, United States), PE-Texas Red-conjugated anti-CD4 (Life Technologies, United States) and Pacific Blue-conjugated anti-CD8 (BD Pharmingen, United States) monoclonal antibody were subsequently added for surface marker staining. The stained cells were washed, fixed and permeabilized by BD FACS fixation/ permeabilization kit (BD Bioscience). Subsequently, PBMC were washed and stained intracellularly with FITC-conjugated anti-IFN-γ (BD Pharmingen, United States), PE-conjugated anti-perforin (Abcam, United States BD-48 clone), PE-Cy7-conjugated anti-TNF-α (BD Pharmingen, United States) and allophycocyanin (APC)-conjugated anti-IL-2 monoclonal antibody (BD Pharmingen, United States) for 30 min. Cells were washed and resuspended in 1% paraformaldehyde prior to flow cytometric analysis. Around 10^6^ cells were acquired on FACS LSR-II flow cytometer (BD Biosciences, United States). FACS data was analyzed by FlowJo (Tree Star, United States). The data with lymphocytes and live cells below 20% of the total population were excluded. The combinations of T cell functions were analyzed by the Boolean combination gate in FlowJo software. T cells with more than or equal to 3 functions were defined as PFCs.

### Isolation of CD3+ T Cells and Cytolysis Assay

CD3+ T cells, which were used as effector cells in this study, were isolated and purified from PBMC of 3 IM patients by negative selection using Magnetic Beads Sorting Kit (Pan T cell isolation kit, Miltenyi, Germany). The purity of isolated CD3+ T cells was determined by staining with anti-CD3 monoclonal antibody, followed by analysis with BD LSRII flow cytometer. Highly purified CD3+ T cells (\>95%) were obtained after sorting. Autologous LCLs (target cells) were stained with 5- and 6-carboxyfluorescein diascetate succinimidyl ester (CFSE) and incubated in 10% FBS/RPMI at 10^6^ cells/ml at 37°C, 5% CO~2~. The purified and stimulated CD3+ T cells (effector cells) were co-cultured with the target cells at a ratio 10:1 for 4 h at 37°C, 5% CO2 and stained with propidium iodide (PI) (Life Technologies). Cells were analyzed by flow cytometry. Percentage of PI positive cells within the CFSE positive population was obtained. Cultures with either autologous LCLs or isolated CD3+ T cells alone served as negative controls.

Statistical Analysis
--------------------

Comparisons of EBV loads in PBMC and plasma amongst the longitudinal samples of IM or AS subjects across the study time points were performed using repeated measure ANOVA. Bonferroni's correction was applied. *P*-value \< 0.0001 was regarded as statistically significant. Comparisons between groups of T cell responses across the study time points were performed by Kruskal--Wallis test and Mann--Whitney Test. *P*-value \< 0.05 was regarded as statistically significant. Prism 6 (GraphPad Software, La Jolla, CA, United States) was used for calculations and illustrations.

Results
=======

Magnitude of IFN-γ Secreting CD8+ T Cell Responses Toward EBV Lytic Peptides Decreased but Those Toward Latent Peptides Increased Over Time in Both IM and AS Individuals
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------

We measured the magnitude of EBV-specific CD8+ T cell responses toward EBV lytic and latent peptides in both IM and AS individuals by IFN-γ ELISPOT assay. HLA typing of 18 PBMC samples of IM patients (IM1--18) and 12 AS individuals (AS 1--12) were performed (Supplementary Table [3](#SM3){ref-type="supplementary-material"}). HLA-class I specific EBV lytic and latent peptides were used to stimulate the PBMC of HLA-class I matched individuals (Supplementary Tables [2](#SM2){ref-type="supplementary-material"}, [3](#SM3){ref-type="supplementary-material"}). The number of spot-forming cells (SFC) per million PBMC of the IM and AS individuals is shown in **Table [1](#T1){ref-type="table"}**. Trend in changes of the EBV antigen-specific T cell response was deduced by comparing the SFC per million PBMC at the earliest time point to that at the longest time point for each study subject (**Table [1](#T1){ref-type="table"}**). Difference in the magnitude of the T cell responses less than or equal to 20 SFC per million PBMC was defined as a stable trend whereas that greater than 20 SFC per million PBMC was defined as an increasing or decreasing trend. As indicated in **Table [1](#T1){ref-type="table"}**, the magnitude of IFN-γ secreting CD8+ T cell responses toward EBV lytic peptides tended to decrease over time from day 0 to 12 months whereas those toward latent peptides tended to increase over time in the majority of IM and AS subjects. The ELISPOT data of 2 representative cases, IM16 and IM17, were shown in **Figure [1](#F1){ref-type="fig"}**. PBMC of IM16 (HLA-type: A2, A26, B46 and cw1) collected at 1, 3, 6, and 12 months post-diagnosis were stimulated by 7 peptide epitopes (TLD, VLK, GLC, YVL, SLR, CLG, VQP). Prominent IFN-γ secreting CD8+ T cell responses against an immediate lytic cycle protein BRLF1-derived peptide (YVL) and a latent cycle protein EBNA3A-derived peptide (VQP) were observed (**Figure [1A](#F1){ref-type="fig"}**). YVL stimulated 793 SFC at 1 month and decreased to 115 SFC at 12 months. In contrast, VQP stimulated 58 SFC at 1 month and increased to 215 SFC at 12 months. IM17 (HLA-type: A1, A11, B4001, B13, Cw7 and Cw10) showed similar trend of T cell responses (**Figure [1B](#F1){ref-type="fig"}**). Response against ATI, the A11-restricted BRLF1-derived peptide, was found to decrease from 2193 to 433 SFC whereas the response against SSCS, the LMP2A-derived peptide, was found to increase from 15 to 180 SFC from 1 to 12 months (**Figure [1B](#F1){ref-type="fig"}**). The decreasing trend of IFN-γ secreting CD8+ T cell responses toward lytic peptides and increasing trend of responses toward latent peptides were observed in the majority of the IM and AS subjects (**Table [1](#T1){ref-type="table"}**). No significant difference between the responses in IM and AS individuals was detected.

###### 

Table showing the T cell responses against HLA-class I restricted EBV lytic and latent peptides determined by ELISPOT.

  Status   Peptide   Protein   Type     D0     D7     1 m    3 m    6 m    12 m   Trend
  -------- --------- --------- -------- ------ ------ ------ ------ ------ ------ ------------
  IM1      SSCS      LMP2A     Latent   \_     3      18     35     45     55     Increasing
  IM1      ATI       BRLF1     Lytic    \_     413    268    65     65     43     Decreasing
  IM1      SEN       BZLF1     Lytic    \_     50     23     18     35     20     Decreasing
  IM2      SSCS      LMP2A     Latent   \_     \_     \_     165    \_     \_     \_
  IM3      VSF       EBNA3B    Latent   1610   \_     \_     2065   \_     \_     Increasing
  IM4      RPP       EBNA3A    Latent   1823   393    603    525    \_     298    Decreasing
  IM4      RPQG      BMRF1     Lytic    533    138    310    293    \_     93     Decreasing
  IM5      YVL       BRLF1     Lytic    \_     \_     813    893    328    \_     Decreasing
  IM5      SSCS      LMP2A     Latent   \_     \_     23     30     123    \_     Increasing
  IM5      ATI       BRLF1     Lytic    \_     \_     453    370    163    \_     Decreasing
  IM6      VSF       EBNA3B    Latent   \_     \_     \_     785    1380   1753   Increasing
  IM6      SLR       EBNALP    Latent   \_     \_     \_     470    365    470    Stable
  IM7      EPL       BZLF1     Lytic    \_     505    \_     1008   \_     805    Increasing
  IM8      SEN       BZLF1     Lytic    \_     3423   2260   1133   \_     1025   Decreasing
  IM9      GLC       BMLF1     Lytic    \_     333    \_     \_     \_     93     Decreasing
  IM9      AVF       EBNA3B    Latent   \_     985    \_     \_     \_     8      Decreasing
  IM9      VQP       EBNA3A    Latent   \_     18     \_     \_     \_     123    Increasing
  IM9      SSCS      LMP2A     Latent   \_     33     \_     90     \_     \_     Increasing
  IM10     IED       LMP2A     Latent   \_     63     \_     1488   413    223    Increasing
  IM10     SEN       BZLF1     Lytic    \_     488    \_     305    245    28     Decreasing
  IM11     SSCS      LMP2A     Latent   \_     0      113    \_     298    \_     Increasing
  IM11     VSF       EBNA3B    Latent   \_     383    563    \_     383    \_     Stable
  IM11     ATI       BRLF1     Lytic    \_     78     80     \_     75     \_     Stable
  IM12     VSF       EBNA3B    Latent   \_     775    \_     \_     393    283    Decreasing
  IM13     VLK       EBNA1     Latent   \_     30     \_     83     \_     258    Increasing
  IM13     SLR       EBNALP    Latent   \_     75     \_     78     \_     88     Stable
  IM14     YVL       BRLF1     Lytic    \_     \_     133    90     25     28     Decreasing
  IM14     AVF       EBNA3B    Latent   \_     \_     8      548    163    178    Increasing
  IM14     IED       LMP2A     Latent   \_     \_     43     525    385    403    Increasing
  IM15     ATI       BRLF1     Lytic    \_     \_     18     53     60     73     Increasing
  IM15     VSF       EBNA3B    Latent   \_     \_     263    225    103    155    Decreasing
  IM15     SSCS      LMP2A     Latent   \_     \_     13     73     78     93     Increasing
  IM16     YVL       BRLF1     Lytic    \_     \_     793    590    260    115    Decreasing
  IM16     VQP       EBNA3A    Latent   \_     \_     58     150    170    215    Increasing
  IM17     SSCS      LMP2A     Latent   \_     \_     15     310    143    180    Increasing
  IM17     ATI       BRLF1     Lytic    \_     \_     2193   1575   663    433    Decreasing
  IM17     SEN       BZLF1     Lytic    \_     \_     65     90     48     20     Decreasing
  IM18     VLK       EBNA1     Latent   \_     \_     \_     375    180    370    Stable
  IM18     SSCS      LMP2A     Latent   \_     \_     \_     128    15     150    Increasing
  AS6      VSF       EBNA3B    Latent   \_     \_     305    530    \_     \_     Increasing
  AS7      AVF       EBNA3B    Latent   \_     \_     0      20     \_     98     Increasing
  AS7      SSCS      LMP2A     Latent   \_     \_     90     510    \_     223    Increasing
  AS7      ATI       BRLF1     Lytic    \_     \_     213    148    \_     28     Deceasing
  AS8      SSCS      LMP2A     Latent   \_     \_     \_     45     168    \_     Increasing
  AS11     AVF       EBNA3B    Latent   \_     \_     \_     185    295    275    Increasing
  AS11     SSCS      LMP2A     Latent   \_     \_     \_     23     95     93     Increasing
  AS12     VSF       EBNA3B    Latent   \_     \_     \_     185    408    273    Increasing

Results are expressed as numbers of spot-forming cells (SFC). "--" represents sample not available.

![IFN-γ producing EBV-specific CD8+ T cell responses in IM16 and IM 17. **(A)** IM16 cells collected at 0, 1, 3, 6, and 12 months post-diagnosis (0, 1, 3, 6, and 12 m) were stimulated with 7 different peptides (TLD, VLK, GLC, YVL, SLR, CLG, and VQP) in duplicate wells. IM16 reacted to only two of the peptides. GLC was shown as representative negative control. **(B)** IM17 cells collected at 0, 1, 3, 6, and 12 months post-diagnosis (0, 1, 3, 6, and 12 m) were stimulated with 5 different peptides (ATI, SSCS, AVF, IED, and SEN) in duplicate wells. IM17 reacted to only two of the peptides. IED was shown as representative negative control. Wells with cells only (blank) were also shown as negative controls. The numbers of spots were shown above the wells. Positive results in histogram were expressed in the mean ± SEM of numbers of spot-forming cells (SFC) per million PBMC.](fmicb-09-00416-g001){#F1}

PBMC and Plasma Viral Loads in Both IM and AS Individuals Decreased Over Time
-----------------------------------------------------------------------------

High PBMC viral loads in IM patients during acute infection and substantial decrease of viral loads over time were observed in previous studies ([@B20]; [@B3]; [@B8]). We also determined the viral loads in both PBMC and plasma of 29 IM patients and 12 AS subjects by qPCR. The median PBMC viral load in IM patients decreased from 21878 EBV copies/million PBMC at diagnosis (D0) to 209 copies/million PBMC at 12 months after diagnosis (**Figure [2A](#F2){ref-type="fig"}**). The median plasma viral loads also decreased from 37154 to 5 copies/mL plasma from day 0 to 12 months (**Figure [2A](#F2){ref-type="fig"}**). Decreases in PBMC and plasma viral loads were also observed in AS individuals (**Figure [2B](#F2){ref-type="fig"}**). In both IM and AS subjects, the PBMC and plasma viral loads peaked at diagnosis and declined substantially afterward. The viral loads were the lowest at the end of the study period, indicating an establishment of effective viral control. Repeated measure ANOVA with Bonferroni's correction was applied for multiple comparisons. Cases which had a complete set of time points (day 0, day 7 and 1, 3, 6, and 12 months) were evaluated by the program. The results showed that the PBMC (*n* = 9) and plasma viral loads (*n* = 7) significantly decreased over time in the IM samples with values \[*F*(5,40) = 12.76, *P* \< 0.0001\] and \[*F*(5,30) = 13.23, *P* \< 0.0001\], respectively. In addition, the PBMC and plasma viral loads at day 7 and 1, 3, 6, and 12 months were significantly lower than those at day 0 (Supplementary Figure [1](#SM4){ref-type="supplementary-material"}).

![PBMC and plasma viral loads of 29 IM patients and 12 AS individuals. **(A)** EBV loads in PBMC and plasma of IM1-29. **(B)** EBV loads in PBMC and plasma of AS1-12. The spots represent the copy numbers of EBV per million PBMC and copy numbers of EBV per mL plasma in different IM and AS individuals collected at Day 0, 7 and 1, 3, 6, and 12 months post-diagnosis (D0, D7, 1 m, 3 m, 6 m, and 12 m). U, undetectable.](fmicb-09-00416-g002){#F2}

Kinetics of Development of CD4+ and CD8+ T Cell Responses to EBV Lytic and Latent Cycle Antigens After Primary Infection
------------------------------------------------------------------------------------------------------------------------

Next, we carried out a detailed characterization of the development of CD4+ and CD8+ T cell responses to several immunodominant EBV lytic and latent antigens in IM patients from primary infection to long term persistence by multi-color flow cytometric assays. Due to the low frequencies of EBV-specific T cells, an expansion of T cells was necessary for the accurate analysis of the subtle changes of functional T cell subsets in the IM patients during different stages of infection ([@B18]; [@B19]). We adopted a T cell expansion protocol provided by Prof. Cliona M Rooney (Baylor College of Medicine, United States) in order to increase the sensitivity of our flow cytometric assay ([@B12]). Such expansion protocol using IL4 and IL7 had been used in different T cell studies and found to maintain the survival of most of the cytokine secreting T cells in similar magnitude ([@B47], [@B48]; [@B12]; [@B43]). To confirm the validity of the flow cytometric assay, we stimulated the PBMC with EBV overlapping peptide pools (EBNA1, EBNA-3A, -3B, -3C and BZLF1) in an IM patient and an EBV-seronegative donor. EBV-specific T cells were clearly detected in the IM patient but not in the seronegative donor except for the pre-loaded perforin in a small proportion of T cells (Supplementary Figure [2](#SM5){ref-type="supplementary-material"}). In addition, the increasing trend of latent antigen-specific IFN-γ secreting CD8+ T cell responses and decreasing trend of lytic antigen-specific responses detected by ELISPOT could also be replicated by this flow cytometric assay (Supplementary Figure [3](#SM6){ref-type="supplementary-material"}).

We proceeded to analyze the EBV-specific T cell responses of 11 longitudinally followed IM patients (IM19-29) toward 4 lytic and 5 latent overlapping EBV peptides. The magnitude of responses was measured as the frequency of responsive T cells which presented at least one function (either IFN-γ, perforin, TNF-α, IL-2, or CD107a) after stimulation by the overlapping peptide pools. No discernible differences in the magnitude and quality of T cell responses were found among the IM patients of different age groups. The overall magnitude of responses of CD4+ T cells to overlapping peptide pools of lytic and latent cycle proteins was similar to that of CD8+ T cells (**Figure [3](#F3){ref-type="fig"}**). At diagnosis, all EBV lytic peptide pools could stimulate both CD4+ and CD8+ T cell responses, presenting a broad response spectrum. Remarkably, the frequency of EBNA3A, 3B and 3C-specific CD4+ and CD8+ T cells clearly increased over time and dominated at 1 year after diagnosis. In contrast, responses toward other EBV lytic and latent peptides were relatively stable throughout the period of our study (**Figure [3](#F3){ref-type="fig"}**).

![Kinetics of development of CD4+ and CD8+ T cell responses to EBV lytic and latent cycle antigens after primary infection. **(A)** Kinetic changes of the percentages of EBV-specific CD4+ T cells and EBV loads. **(B)** Kinetic changes of the percentages of EBV-specific CD8+ T cells and EBV loads. T cells were expanded by overlapping peptide pools for 5 days and re-stimulated by the corresponding peptide pools for 6 h before flow cytometric assays. Each bar represents the mean percentages of EBV-specific T cells in the 11 IM patients (IM 19--29) at different time points. The corresponding viral loads in PBMC (blue curve) and plasma (green curve) at different time points are shown. Each dot in the line curve represents the mean viral load of the 11 IM patients.](fmicb-09-00416-g003){#F3}

Diversity of CD4+ and CD8+ Polyfunctional T Cells (PFC) Responses Increased Over Time
-------------------------------------------------------------------------------------

Polyfunctional T cells, which execute multiple functions upon stimulation by a specific antigen, were reported to elicit stronger immune responses ([@B4]; [@B1]; [@B45]). We examined the evolution of the magnitude and functionality of lytic and latent cycle antigen-specific CD4+ and CD8+ T cells. The functional profiles of CD4+ and CD8+ PFC (with three or more functions) of a representative case, IM 25, are shown in **Figure [4](#F4){ref-type="fig"}**. Low percentages of lytic and latent antigen-specific CD4+ and CD8+ responsive T cells with 2 or more functions appeared at diagnosis. The CD4+ and CD8+ responsive T cells against the latent antigen EBNA3B increased dramatically over time. Particularly, the frequency of EBNA3B-specific CD8+ PFC increased from approximately 1% at diagnosis to 30% of total antigen-reactive CD8+ T cells at 12 months after diagnosis. In contrast, BZLF1-responsive cells decreased over time and EBNA1- responsive cells remained stable across the time points from day 0 to 12 months (**Figures [4A,B](#F4){ref-type="fig"}**). At day 0, most of the CD4+ and CD8+ PFC only displayed a restricted number of combinations of functions. Very low percentages of 4-functional CD4+ PFC (IFNγ+/IL-2+/perforin+/TNF-α+) and 3-functional CD8+ PFC (CD107a+/IL-2+/TNF-α+) were detected (**Figures [4A,B](#F4){ref-type="fig"}**). At later time points, these CD4+ and CD8+ PFC became more highly functional as 4- and 5-functional T cells started to emerge. Interestingly, a dramatic increase in the diversity of functional subsets of both CD4+ and CD8+ T cells was observed (**Figures [4C,D](#F4){ref-type="fig"}**). Such diverse functional subsets were found in 8 out of the 11 IM cases whereas the remaining 3 cases showed a constant level or slightly decreased variety of combination of functions in the later time points (Supplementary Figure [4](#SM7){ref-type="supplementary-material"}).

![Longitudinal functional profiles of EBV-specific T cells in one representative IM patient (IM25). The pie charts represent the proportions of **(A)** CD4+ T cells and **(B)** CD8+ T cells with single (green), double (red), triple or more (blue) functions upon stimulation with BZLF1, EBNA3B, and EBNA1 overlapping peptide pools. T cells were expanded with 4 lytic and 5 latent antigens overlapping peptides pools for 5 days and re-stimulated by the corresponding peptide pools for 6 h before flow cytometric assays. Flow cytometric assays were performed at an early time point ranged from D0 to 3 m, a middle time point ranged from 3 to 6 m and a late time point ranged from 6 to 12 m. D0, at diagnosis; 6 m, 6 months after diagnosis; 12 m, 1 year after diagnosis. The percentages of responsive **(C)** CD4+ and **(D)** CD8+ T cells with different combinations of functions upon stimulation by BMLF1, BRLF1, BZLF1, EBNA1, EBNA3A, EBNA3B and EBNA3C at diagnosis (D0) and 1 year after diagnosis (12 m). d, CD107a; g, Interferon-gamma; 2, Interleukin-2; p, Perforin; t, Tumor-necrosis factor-alpha.](fmicb-09-00416-g004){#F4}

Emergence of CD4+ and CD8+ Polyfunctional T Cell Responses Toward EBV Lytic and Latent Antigens
-----------------------------------------------------------------------------------------------

We summarized the development of EBV-specific CD4+ and CD8+ PFC for all IM patients (**Figure [5](#F5){ref-type="fig"}**). EBV lytic and latent cycle antigen-specific CD4+ PFC (with three or more functions) existed at diagnosis but the mean frequencies were less than 3% of total responsive CD4+ T cells (**Figure [5A](#F5){ref-type="fig"}**). The mean frequencies of CD4+ PFC against lytic and latent cycle antigens did not change significantly over time from primary infection to long term persistent stage. The abilities of EBV lytic and latent cycle antigen-specific CD8+ T cells to generate PFC were relatively stronger when compared with CD4+ cells and appeared to change over time (**Figure [5B](#F5){ref-type="fig"}**). During acute infection, the mean frequencies of EBV-specific CD8+ PFC were less than 3% of the total responsive CD8+ T cells after stimulation. The percentages of CD8+ PFC against early lytic antigen, BMLF1, BRLF1 and BZLF1, increased slightly whereas those of CD8+ PFC against the latent antigens, EBNA3A, 3B and 3C, increased significantly over time. Other subdominant antigens such as EBNA1, LMP2 and GP350 did not stimulate any significant changes in the proportion of PFC. Although the PFC responses were induced by the immunodominant latent antigens derived from EBNA3A-C in most of the IM patients (**Figure [5](#F5){ref-type="fig"}**), it should be noted that PFC responses could also be induced by antigens derived from immediately early (BZLF1 and BRLF1) and early (BMLF1) EBV proteins in some individuals (Refer to **Figures [4](#F4){ref-type="fig"}, [5](#F5){ref-type="fig"}** and Supplementary Figure [4](#SM7){ref-type="supplementary-material"}). Taken together, our data suggested that the CD4+ and CD8+ T cells specific to the immunodominant EBV proteins, including BZLF1, BRLF1, BMLF1, EBNA-3A, -3B, and -3C, became highly functional during the long term persistent phase.

![Development of EBV lytic and latent antigen-specific polyfunctional T cells from acute primary infection stage to long-term persistence. **(A)** CD4+ T cells and **(B)** CD8+ T cells in 11 IM patients. T cells were expanded by overlapping peptide pools for 5 days and re-stimulated by the corresponding peptide pools for 6 h before flow cytometric assays. Each bar represents the mean ± SEM percentages of polyfunctional T cells (three or more functions after stimulation) out of total EBV-specific T cells upon stimulation with a specific latent overlapping peptide pool.](fmicb-09-00416-g005){#F5}

Increased Cytotoxicity of T Cells Against Autologous LCL in IM Patients Over Time
---------------------------------------------------------------------------------

Cytotoxicity assay was carried out to examine whether increased polyfunctionality is accompanied by enhanced cytotoxicity of EBV-specific T cells. T cells were stimulated and expanded by overlapping peptide pools from the immunodominant EBNA3A or 3B protein of each donor. The CD3+ T cells were then purified by negative selection using Miltenyl Magnetic Beads Cell Sorting system. The purity of the T cells was on average greater than 95%, and the viability of T cells after sorting did not change significantly.

The cytotoxicity of T cells against autologous LCL, after stimulation with EBNA3 overlapping peptide pools, was assessed longitudinally for three IM patients (**Figure [6A](#F6){ref-type="fig"}**). The cytotoxicity of T cells against LCL increased over time. These results were consistent with elevated frequencies of perforin- and CD107a-expressing T cells (**Figure [6B](#F6){ref-type="fig"}**). Cytotoxic potential was further enhanced by stimulating the T cells with EBNA3 overlapping peptide pools for 5 days prior to setting up the lysis assay, concurrent with increasing polyfunctionality, perforin production, and degranulation (**Figure [6B](#F6){ref-type="fig"}**).

![Cytotoxicity of EBNA3-specific T cells against autologous LCLs in three IM patients. T cells were expanded for 5 days in the presence of overlapping peptide pools of EBNA3A or EBNA3B. Autologous B-LCL (target cells) were stained with CFSE and co-cultured with activated purified T cells (effector cells) for 4 h at an Effector/Target ratio of 10:1. Dead cells were discriminated from live cells by propidium iodide (PI). Autologous LCLs were killed by T cells. The percentage of specific lysis is calculated by subtracting the background (LCL co-cultured with unstimulated T cells). **(A)** Cytotoxicity of EBNA3-specific T cells at different time points in 3 IM patients. PBMC of IM20 and IM21 and IM25 patients were stimulated and expanded with overlapping peptide pools of EBNA3A and EBNA3B, respectively. U, LCL co-cultured with unstimulated T cells. **(B)** Development of Perforin producing T cells (upper row) and CD107a positive T cells (lower row) in IM25.](fmicb-09-00416-g006){#F6}

Discussion
==========

Identification of polyfunctional CD8+ T cells in the immune control of viral infection had been reported ([@B4]; [@B1]; [@B45]). However, most of these studies focused on assessing CD8+ T cell responses to human immunodeficiency virus (HIV) and their mechanisms in killing. Much less is known about the role of PFC responses in the control of stable persistent DNA virus such as EBV. Here, we describe a comprehensive study in which the development of EBV-specific CD4+ and CD8+ T cells, as well as their magnitude and polyfunctionality were monitored from primary infection to long-term persistence in two cohorts of children with infectious mononucleosis (IM) and asymptomatic (AS) primary EBV infection, respectively.

The IFN-γ secreting CD8+ T cells were characterized as the major population of T cells participating in viral control ([@B6]; [@B42]). IFN-γ ELISPOT assay became a common quantitative detection method of virus-specific CD8+ cells ([@B23]; [@B49]). A previous study had demonstrated the diagnostic potential of IFN-γ and IL-2 ELISPOT assays in distinguishing active and latent tuberculosis in children infected with *Mycobacterium tuberculosis* ([@B9]). In the present study, the kinetics of IFN-γ producing CD8+ T cell responses in IM patients and AS subjects was first assessed by ELISPOT assay. The decreasing pattern of IFN-γ producing CD8+ T cell responses toward EBV lytic peptides and increasing pattern of T cell responses toward EBV latent peptides were identified over time in both IM and AS subjects. There was no discernible difference in the trend of evolution of T cell responses in these two study cohorts. However, this widely accepted IFN-γELISPOT assay using HLA-type restricted epitopes to detect EBV antigen-specific T cells could not simultaneously assess the CD4+ cell responses and determine the expression of other functional cytokines ([@B7]; [@B39]). The difficulties in choosing the specific EBV peptides across a wide range of HLA alleles also restricted the panel of antigen-specific cells to be tested which could result in missing of potentially important information (Supplementary Tables [2](#SM2){ref-type="supplementary-material"}, [3](#SM3){ref-type="supplementary-material"}).

Accumulating evidence indicated that the "quality" of T cell responses should be assessed by functionality ([@B41]). The more functions the T cells possess, the more robust the immune protection they can provide ([@B27]). We have also shown that long term carriers could generate robust PFC responses against lytic and latent EBV antigens with the greatest responses toward the immunodominant epitopes of the EBNA3 proteins ([@B31]). However, the time of emergence of PFC responses against EBV lytic or latent antigens, differences between CD4+ and CD8+ T cell responses, and concurrent EBV loads in PBMC and plasma from acute to chronic stage of infection are not clearly understood. To address these questions, we performed a longitudinal study to assess the development of PFC responses to EBV in 11 IM patients. We assessed five functional parameters: IFN-γ, TNF-α, IL-2, perforin, and CD107a, all of which are typical functions of T cells that were reported in previous studies ([@B14]; [@B32]; [@B34]; [@B27]). T cells with three or more functions after stimulation are defined as PFC. EBV-specific lytic and latent antigen-derived overlapping peptides were used to stimulate both CD4+ and CD8+ T cell responses. Similar trend of response of IFN-γ specific CD8+ cells was observed as that detected by ELISPOT assay, validating the reliability of data generated by both methods (Supplementary Figure [3](#SM6){ref-type="supplementary-material"}). In the IM patients, EBV-specific CD4+ and CD8+ PFC were detectable at diagnosis toward lytic and latent cycle antigens. These CD4+ and CD8+ PFC only displayed a restricted combination of functions, such as the 4- functional CD4+ PFC (IFNγ+/IL-2+/perforin+/TNF-α+) and the 3-functional CD8+ PFC (CD107a+/IL-2+/TNF-α+) (refer to **Figure [4](#F4){ref-type="fig"}**). At later time points, these CD4+ and CD8+ PFC became more highly functional as 4- and 5-functional T cells started to emerge. The development of PFC responses toward different specific peptides varied among the individuals. In most of the IM patients, the PFC responses were induced by the immunodominant antigens derived from EBNA3A-C (**Figure [5](#F5){ref-type="fig"}**). Interestingly, in some of the individuals, antigens derived from immediately early (BZLF1 and BRLF1) and early (BMLF1) EBV proteins induced the highest proportion of CD8+ as well as CD4+ PFCs (refer to **Figures [4](#F4){ref-type="fig"}, [5](#F5){ref-type="fig"}** and Supplementary Figure [4](#SM7){ref-type="supplementary-material"}). In addition, low frequencies of EBNA1-specific CD4+ T cells were detected at both diagnosis and 6 and 12 months in some IM patients (Supplementary Figure [4](#SM7){ref-type="supplementary-material"}), in contrast to the findings of previous studies in which EBNA1-specific CD4+ T cells were not detected until months after the initial diagnosis ([@B25]; [@B37]). Since EBNA1-specific effector T cells might be important in the control of EBV-positive lymphoproliferative diseases ([@B19]), it is interesting to follow whether the proportion of EBNA1-responsive PFC would increase at longer time points in the future. Diverse combinations of three or more functions of both antigen-specific CD4+ and CD8+ T cells were shown to emerge at 6--12 months, suggesting a potential co-operative relationship between the CD4+ and CD8+ PFC in the long term viral control (**Figures [4C,D](#F4){ref-type="fig"}** and Supplementary Figure [4](#SM7){ref-type="supplementary-material"}). Presence of CD107a+ and perforin-releasing cytotoxic CD4+ PFC was demonstrated in this study (**Figure [4C](#F4){ref-type="fig"}**). Similarly, a rare population of CD4+ cytotoxic T cells was previously identified in the patients with chronic viral infection of CMV ([@B7]). The presence of cytotoxic CD4+ PFC indicates that CD4+ T cells may also play a direct role in the control of persistent EBV infection. The clinical preparation of virus-specific T cells for the control of post-transplant lymphoproliferative disorders was shown to require the presence of CD4+ T cells ([@B12]; [@B24]). In fact, CD4+ PFC was found to be molecularly distinct from IFN-γ mono-functional CD4+ T cells and associate with favorable clinical outcomes in patients with *Plasmodium falciparum* infection ([@B5]). Taken together, our data clearly demonstrated the development and maturation of both CD4+ and CD8+ PFC from early to long term infection stages in IM patients.

Decreasing patterns of EBV loads in PBMC and plasma were illustrated in both IM and AS subjects (**Figure [2](#F2){ref-type="fig"}**), indicating that both study subjects were capable of generating sufficient T-cell immunity for viral control. Moreover, the viral loads *per se* could not explain the development of IM symptoms in some individuals, although elevated viral loads were observed in both IM and AS individuals during acute EBV infection ([@B44]). Manifestation of the self-limiting immunopathological conditions arising in IM patients might be related to the inadequate NK cell cytotoxicity toward infected cells during acute infection ([@B37]). In both IM and AS subjects, plasma loads declined dramatically to low or undetected levels, yet, PBMC viral loads showed a slower decline (**Figure [2](#F2){ref-type="fig"}**). The sharp decrease in plasma loads was probably due to the initial control by NK cell and the early lytic cycle antigen-specific CD8+ T cell responses. In contrast, the slow decline of PBMC was due to the gradual emergence of both lytic and latent antigen-specific polyfunctional CD4+ and CD8+ T cell responses at about 6 months. Indeed, a natural decay of PBMC viral loads in the early stage of infection independent of EBV-specific T-cell immunity was previously proposed ([@B13]). The viral control thereafter was probably mediated by the development and strengthening of PFC responses toward the immunodominant antigens derived from BZLF1, BRLF1, BMLF1, EBNA3A, 3B and 3C proteins from about 6 to 12 months post-infection. The sustained decline of EBV loads during this period correlated well with the emergence of T cells capable of presenting multiple functions. To further assess whether increased PFC responses correlated to viral control in the IM patients, a cytotoxic assay was performed. We stimulated the T cells of three IM patients with EBNA3A or EBNA3B peptide pools and found a steady increase in cytotoxicity of T cells against autologous LCL over time (**Figure [6](#F6){ref-type="fig"}**). The increasing proportions of EBNA3A- or EBNA3B-specific PFC correlated with the enhanced cytotoxic capacities, supporting that effective viral control was achieved by the capability to generate highly functional T cells.

Conclusion
==========

EBV antigen-specific CD4+ and CD8+ PFC responses emerge during the first year of primary EBV infection, with greatest responses toward immunodominant epitopes in both lytic (BZLF1, BRLF1 and BMLF1) and latent (EBNA3A-C) proteins, correlating to steady decline in PBMC and plasma viral loads.
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